Atrial Fibrillation Trial, Recruiting NCT04005508 Sponsor: National University of Singapore Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT04005508
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 22 or older.
  • People who have been diagnosed with atrial fibrillation (an irregular heartbeat), including any type — occasional, ongoing, or continuous.
  • People who have at least one of the following heart or health risk factors: high blood pressure; diabetes; a history of stroke; significant blockages in the heart's arteries (confirmed by scans, stress tests, or previous heart procedures); a form of chronic kidney disease (not including polycystic kidney disease) where the kidneys are not working at full capacity; a 10-year cardiovascular disease risk score of 15% or higher based on a standard risk calculator called the Framingham risk score; or being aged 75 or older.

Who may not be able to join:

  • People who have already been diagnosed with obstructive sleep apnoea and are regularly using a CPAP machine (a breathing device used during sleep).
  • People whose atrial fibrillation is linked to certain heart valve problems, specifically moderate or severe narrowing of the mitral valve, or the presence of a mechanical heart valve.
  • People who have a permanent pacemaker already implanted.
  • People whose other medical conditions mean their life expectancy is estimated to be less than one year.
  • People who are not able to give their own consent to participate in research.
  • Women who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chi-Hang R Lee, MD, National University of Singapore

Phone: 67795555

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
National University of Singapore
Registry
ClinicalTrials.gov
Start date
1 July 2019
Est. completion
30 June 2025

Where this trial is recruiting

🇸🇬 Singapore

Primary endpoints

Major adverse cardiovascular events

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov